Last reviewed · How we verify
SODIUM PERTECHNETATE TC 99M
Sodium Pertechnetate TC 99M is a marketed radiopharmaceutical with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and widespread use in diagnostic imaging. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | SODIUM PERTECHNETATE TC 99M |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (PHASE1)
- A Phase 2/3,PSMA-T4, Prostate Cancer (NA)
- The Absorption Rate of Subcutaneous Infused Fluid
- An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery (PHASE1)
- A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication
- Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo (PHASE3)
- Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODIUM PERTECHNETATE TC 99M CI brief — competitive landscape report
- SODIUM PERTECHNETATE TC 99M updates RSS · CI watch RSS